Aloxi is a potent and long-lasting antiemetic belonging to the second generation of serotonin (5-HT3) antagonists, the leading class for the prevention of nausea and vomiting induced by chemotherapy.
The product is already commercialized in the US, where over three million treatments have been completed successfully. Aloxi is currently on the market in some European countries, as well as in several countries of Latin America, where the trade name is Onicit.
In 2004 the US National Comprehensive Cancer Network guidelines indicated Aloxi as the treatment of choice for the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapies. However, there is still a medical need for a better prevention of nausea and vomiting due to chemotherapy treatments.
“We are delighted to sign this new agreement with Biovitrum and look forward to initiating a successful co-operation for Aloxi in the Nordic territory”, said Dr Riccardo Braglia, managing director of Helsinn Healthcare. “We are pleased that the patients and the medical community in this region will enjoy the benefits of an innovative antiemetic like Aloxi.”